Archive: 19/12/2013

AstraZeneca pays $4.1 billion for diabetes buyout (Update)

Anglo-Swedish drugmaker AstraZeneca PLC will buy out Bristol-Myers Squibb Co.'s stake in their partnership to develop and sell diabetes drugs in a deal worth $4.1 billion—seizing an opportunity to serve the projected explosion ...

page 11 from 11